Rak jelita grubego: badanie kliniczne fazy III

Kryteria włączenia kto może wziąć udział (13)

1. Newly diagnosed biopsy-confirmed colon cancer (adenocarcinoma) with macroscopic suspicion of submucosal invasion considered removable by EFTR as deemed by the local multidisciplinary team (MDT) at the participating center
2. Size ≤20 mm in diameter as deemed by the colonoscopist
3. No presence of histopathological high-risk features in biopsy (high grade tumor growth, budding grade 2 or 3, or lymphovascular invasion)
4. Patient eligible for surgical removal as deemed by the local MDT at the participating center
5. Endoscopic images or video of the tumor
6. No sign of disease beyond T2N0M0 on pre-treatment imaging, biopsy sampling, and radiographic and clinical evaluation
7. No contraindication for any of the two treatment arms
8. Written informed consent
9. No prior or synchronous CRC
10. No other malignancy which is not cured
11. No more than 10 adenomas or serrated polyps
12. No genetic cancer syndrome (adenomatous or serrated polyposis syndrome; Lynch or Lynch-like syndrome)
13. No inflammatory bowel disease